J Korean Neurol Assoc.  2020 May;38(2):88-99. 10.17340/jkna.2020.2.2.

Calcitonin Gene-Related Peptide Targeting Therapies for Migraine: A New Era for Migraine Treatment

• Park HK
• Kim BK

• KMID: 2501754
• DOI: http://doi.org/10.17340/jkna.2020.2.2

Abstract

Development of medications targeting the trigeminal sensory neuropeptide calcitonin gene-related peptide (CGRP) or its receptor has ushered in the new era for the treatment of migraine. Some of these drugs are approved by the USA Food and Drug Administration and European Medicines Agency since 2018, and others are in the process of approval. Since the CGRP-related therapies act directly on the migraine pathophysiology, they have advantages over conventional treatments not only in effect but also in terms of adverse effects. CGRP receptor antagonist have an effect on both acute and preventive treatment of migraine, while monoclonal antibodies for CGRP ligand (fremanezumab, galcanezumab, and eptinezumab) or receptor (erenumab) reduce migraine frequency and related disability. Galcanezumab was approved by the Ministry of Food and Drug Safety in Korea in September 2019. As of December 2019, it is available for use in adult patients with migraine. We describe the pathophysiology of CGRP in migraine, summarize the results of recent CGRP antagonism related clinical trials, and provide opinions about the use of CGRP-related therapies in clinical practice.

Keyword

Calcitonin gene-related peptide; Migraine disorders; Monocloncal antibodies; Calcitonin gene-related peptide antagonists